With the ongoing global surge in COVID-19 cases, limited information about 2019-nCoV, and lack of a definitive cure, the drug repurposing approach looks like the most promising tool to combat COVID-19. Under such circumstances, until recently, HCQ has turned out as valuable yet controversial therapeutics for its punitive role against COVID-19. As a result, a sumptuous amount of effort has been put forward to validates its therapeutic role for treating COVID-19 by extensive preclinical/clinical trials. On 17 June 2020, WHO announced the stoppage of HCQ Solidarity trial to find an effective COVID-19 treatment. However, the decision to stop HCQ's use in the Solidarity trial does not apply to the use or evaluation of hydroxychloroquine in pre-or post-exposure prophylaxis in patients exposed to COVID-19. Whatever it takes, the HCQ remains the WHO Model Essential Medicine and its accessibility to the people around the globe is an on-going demand. This in-turn demands cost-effective, safer, and environment-friendly large-scale synthesis of HCQ. In this context, inducing variability in raw materials via cheap and eco-green approach is the utmost essential to building a sustainable production particularly for small and medium scale enterprises (SMEs).